The RADAR-CNS (Remote assessment of disease and relapse – Central Nervous System) programme aims to improve patients’ quality of life, and potentially to change how these and other chronic disorders are treated.

P1vital Products Limited have developed a technology that has the potential to reduce the amount of time it takes to detect whether a patient is responding to a particular antidepressant medication.

The QbTest Utility in Optimising Treatment for ADHD (QUOTA) study investigates how we might achieve the optimal medication dose for people with ADHD.